Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAFIR ABC10 targeted maintenance versus standard care in advanced biliary cancer
2023-508100-38-00Phase 3Authorised
- Sponsor
- Unicancer
- Start
- Jun 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of ivosidenib, trastuzumab, neratinib, niraparib, encorafenib and 7 more in biliary cancer (2 arms), sponsored by Unicancer. Primary endpoint: Progression-free survival. Planned start Jun 2024; status: authorised.
02
Drugs
03
Conditions
biliary cancer
Beyond the preview
Go deeper on 2023-508100-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508100-38-00.